Clinical trials: SC Disease
Pharmacokinetics of ASP2408, Healthy Subjects
A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) after intravenous (IV) administration of ASP2408 manufactured from a new production clone and also following single ascending doses of…
- Trial name
- NCT02150070
- Testing
- ASP2408
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Adenoma, Colo-rectal Cancer
A Dual Tandem Study - SC vs. CAD-EYE vs. CAD-EYE With G-EYE
Single-center, four-arm dual-tandem, randomized, open-label study involving the following devices: 1. The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques …
- Trial name
- NCT05318495
- Testing
- Standard Colonoscopy, CAD-EYE, G-EYE
- Where
- Germany
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Dr. Horst Schmidt Klinik GmbH
Diabetes Mellitus, Type 2
Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function
Primary objective: To compare the pharmacokinetic profile of Glymera (PB1023) Injection after a single dose administered by subcutaneous injection to subjects with normal renal function and impaired renal function.
- Trial name
- NCT01478399
- Testing
- PB1023 Injection
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Neutropenia (Low White Blood Cell Count)
A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)
This is a study comparing two study drugs, Filgrastim Hospira and Neupogen®. Neupogen® is approved by the US Food and Drug Administration (FDA) to treat low numbers of specific kinds of white blood cells (WBC) known as…
- Trial name
- NCT02766634
- Testing
- Filgrastim Hospira (US), U.S.-approved Neupogen®
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections
A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants
An open-label, two part study to assess the safety, tolerability, and PK of VH3810109 in healthy adult participants. Participants will receive a single SC or IV dose of VH3810109 co-administered with rHuPH20 and will be followed…
- Trial name
- SPAN (NCT05291520)
- Testing
- VH3810109, rHuPH20
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Systemic Lupus Erythematosus
Japanese phase1 Study of Belimumab (IV vs SC)
This study is an open-label, randomized, 2 parallel group, single dose study in healthy Japanese males to assess the pharmacokinetics and safety/tolerability of single intravenous administration and single subcutaneous…
- Trial name
- NCT01516450
- Testing
- GSK1550188 IV, GSK1550188 SC
- Where
- Japan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Pergoveris FD and Liquid China BE Study
The main purpose of this study is to assess the bioequivalence (BE) of the fixed combination of follitropin alfa and lutropin alfa in Pergoveris freeze-dried (FD) (Test 1) or in Pergoveris Liquid (Test 2) versus the…
- Trial name
- NCT04899193
- Testing
- Pergoveris FD, Pergoveris Liquid, Gonal-f
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Alzheimer Disease
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
- Trial name
- NCT06511570
- Testing
- sabirnetug (ACU193), Sabirnetug + rHuPH20
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Acumen Pharmaceuticals
Systemic Lupus Erythematosus (SLE)
SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC…
- Trial name
- NCT06144710
- Testing
- SG301 SC Injection
- Where
- 10 sites in China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
SARS-CoV-2 Infection
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
The primary objectives of this open-label trial were to evaluate the safety and pharmacokinetics (PK) of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) administered intramuscularly (IM), subcutaneously…
- Trial name
- NCT05142306
- Testing
- COVID-HIG
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Diabetes Mellitus
Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone
Insulin lispro and regular human insulin are Food and Drug Administration (FDA)-approved medications for the treatment of diabetes mellitus.
- Trial name
- NCT00862849
- Testing
- Insulin Lispro, Regular Human Insulin, rHuPH20
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Halozyme Therapeutics
Sickle Cell Disease, Sickle-Cell; Hb-SC
A Study of IMR-687 in Healthy Adult Volunteers
The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, PK and PD profile of the orally administered IMR-687 in healthy adult subjects.
- Conditions
- Sickle Cell Disease, Sickle-Cell; Hb-SC, Sickle Beta 0 Thalassemia
- Trial name
- NCT02998450
- Testing
- IMR-687
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Healthy Volunteers, Diabetes Mellitus, Type 2
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin).
- Conditions
- Healthy Volunteers, Diabetes Mellitus, Type 2, Overweight, Obesity
- Trial name
- NCT04189848
- Testing
- Semaglutide, Dulaglutide
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Alzheimer Disease
Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers
This study is to evaluate the safety and tolerability of single dose of GB-5001 (donepezil) IM and SC depot in healthy male Adults.
- Trial name
- NCT06127368
- Testing
- GB-5001A, GB-5001D, Oral cohort
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- G2GBio, Inc.
Diabetes Mellitus
Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler
Evaluation of the pharmacokinetics and pharmacodynamics of different doses of spray-dried recombinant human insulin powder for inhalation administered via a dry powder uinhalation device compared with subcutaneously administered…
- Trial name
- NCT00426920
- Testing
- Insulin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- QDose Limited
Coronary Disease
A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4
This study is designed to assess tolerability of the weight-adjusted dose of RUC-4 (mg/kg) required to achieve 80% or more inhibition of the initial slope of platelet aggregation to 20 µM ADP by Light Transmission Aggregometry…
- Trial name
- NCT03844191
- Testing
- RUC-4 Compound
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- CeleCor Therapeutics
Healthy Volunteers
Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.
A study to evaluate and compare the PK profiles of abaloparatide-SC 80 μg and abaloparatide-sMTS 300 μg in a cohort of healthy men and to make a similar evaluation in a cohort of healthy women
- Trial name
- NCT04663464
- Testing
- abaloparatide-sMTS, abaloparatide-SC
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Radius Health, Inc.
Osteoporosis
Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.
A study to evaluate the bioequivalence of abaloparatide between 2 abaloparatide-sMTS treatments 300 μg treatments applied to the thigh for 5 minutes.
- Trial name
- NCT04936984
- Testing
- abaloparatide-sMTS (Patheon), abaloparatide-sMTS (Kindeva)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Radius Health, Inc.
Multiple Sclerosis
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and…
- Trial name
- NCT01085318
- Testing
- Rebif
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- EMD Serono
Overweight and Obesity
Phase Ib Clinical Study of HDM1005 Injection
This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation study in overweight or obese subjects to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD)…
- Trial name
- NCT06637020
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.